Europe Considers Black Box Warnings - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Europe Considers Black Box Warnings


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Commission (EC) is seeking to introduce a black symbol to identify medicines that are subject to additional monitoring. A public consultation has been launched for stakeholders to comment on the phasing-in of requirements for such a symbol. The black symbol would be placed in the product information along with the statement: “This medicinal product is subject to additional monitoring”.

Among other points, the EC is interested in hearing about the practicalities of adapting existing product information to the new requirements, particularly the time needed for companies to make the necessary amends. The symbol will need to be applied to all currently marketed products that fall within the scope of the additional monitoring requirements. As such, companies will have to adapt their packaging leaflets, which will be subject to a regulatory procedure by means of a variation.

Additional monitoring is an important part of Europe’s new pharmacovigilance legislation and the symbol will be an important communication and awareness-rising tool. The EC wants to make healthcare professionals and patients aware of products that are subject to additional monitoring to initiate more targeted supervision of such products and to encourage the reporting of any specific, related observations.

All comments must be received by Jan. 10, 2013.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here